KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBIT (2016 - 2025)

Exact Sciences (EXAS) has disclosed EBIT for 16 consecutive years, with -$82.6 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 90.58% to -$82.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$206.3 million through Dec 2025, up 80.33% year-over-year, with the annual reading at -$206.3 million for FY2025, 80.33% up from the prior year.
  • EBIT for Q4 2025 was -$82.6 million at Exact Sciences, down from -$25.5 million in the prior quarter.
  • The five-year high for EBIT was $6.8 million in Q3 2023, with the low at -$876.4 million in Q4 2024.
  • Average EBIT over 5 years is -$146.0 million, with a median of -$101.4 million recorded in 2024.
  • The sharpest move saw EBIT surged 104.96% in 2023, then tumbled 1191.77% in 2024.
  • Over 5 years, EBIT stood at -$221.4 million in 2021, then surged by 46.32% to -$118.9 million in 2022, then skyrocketed by 42.93% to -$67.8 million in 2023, then crashed by 1191.77% to -$876.4 million in 2024, then skyrocketed by 90.58% to -$82.6 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$82.6 million, -$25.5 million, and -$2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.